Feb 5, 2024 8:00 am EST Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Jan 24, 2024 4:10 pm EST Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2024 8:00 am EST Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
Nov 30, 2023 8:00 am EST Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
Nov 27, 2023 4:38 pm EST Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 27, 2023 8:00 am EST Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
Nov 13, 2023 8:00 am EST Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
Nov 3, 2023 3:43 pm EDT New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
Nov 2, 2023 8:00 am EDT Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Nov 1, 2023 4:52 pm EDT Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)